1) Leadership Transition and Strategic Vision
- Brett Sandercock announced his retirement, with Aaron Blumer appointed as the new CFO, bringing over 17 years of financial leadership experience.
- Michael J. Farrell emphasized the ongoing execution of the global 2030 strategy aimed at accelerating business growth and delivering long-term shareholder value.
- The company continues to focus on operational excellence and innovation, underlining its commitment to enhancing patient care through digital health solutions.

2) Financial Performance and Segment Results
- ResMed reported Q3 FY2026 revenue of $1.43 billion, an 11% increase YoY (8% growth in constant currency).
- Non-GAAP earnings per share grew by 21%, supported by a 290 basis points YoY gross margin increase, now at 62.8%.
- Operating profit rose 18%, with an operating margin of 36.7%. Free cash flow reached $520 million, maintaining a conversion rate above 100%.

3) Market Dynamics and Competitive Landscape
- The company is experiencing strong growth in its device and mask segments, particularly with the new fabric-based masks like the AirTouch N30i, which has shown 6% higher compliance than silicone alternatives.
- ResMed's device sales in the U.S., Canada, and Latin America increased by 6%, while masks and other sales rose by 14%.
- The competitive landscape remains stable, with no significant market share shifts noted from recent product launches by competitors.

4) Operational Initiatives and Product Development
- ResMed continues to invest in supply chain optimization and innovation, with a focus on new product launches and enhancements to existing offerings.
- The company announced the acquisition of Noctrix Health for $340 million, expected to close on June 1, 2026, which will expand ResMed's portfolio into treating restless leg syndrome.
- The ongoing rollout of the AirSense 11 platform and the introduction of new mask technologies are key drivers for future growth.

5) Guidance and Future Outlook
- ResMed maintains its outlook for high single-digit revenue growth and earnings growth exceeding revenue growth through fiscal 2030.
- The company expects continued gross margin improvements despite potential cost inflation in components and logistics.
- There is a strong focus on leveraging GLP-1 therapy trends to enhance patient adherence to CPAP therapy, with ongoing investments in digital health solutions.

Bottom line: ResMed Inc. is positioned for sustained growth with a strong financial foundation, innovative product offerings, and strategic acquisitions, making it a compelling investment opportunity for shareholders amidst a dynamic healthcare landscape.